Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6337069 | 0.85 | CA1 (0.46) | CA1CA2CA7CA9HTT | |
| SCHEMBL6337071 | 0.85 | CA1 (0.46) | CA1CA2CA7CA9HTT | |
| SCHEMBL291860 | 0.83 | CA1 (0.42) | CA1CA2CA7CA9HTT | |
| SCHEMBL291859 | 0.83 | CA1 (0.42) | CA1CA2CA7CA9HTT | |
| SCHEMBL8376755 | 0.81 | ALDH1A1 (0.44) | ALDH1A1TSHRNPC1 | |
| SCHEMBL5516567 | 0.80 | LMNA (0.51) | NPSR1ALOX15MAPT | |
| SCHEMBL9489505 | 0.80 | HTT (0.49) | CA1CA2CA7CA9HTT | |
| SCHEMBL9489307 | 0.80 | HTT (0.49) | CA1CA2CA7CA9HTT | |
| SCHEMBL9489310 | 0.80 | HTT (0.49) | CA1CA2CA7CA9HTT | |
| SCHEMBL7789021 | 0.80 | ALDH1A1 (0.55) | ALDH1A1CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960379-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960379-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7897629-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897629-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897629-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090247594-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247594-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247594-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009114744-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233931-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20090233931-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2009-09-17 | — | — | US | disclosed |
| US-7557095-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557095-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-2044041-A2 | ISOTHIAZOLIDINES USEFUL IN THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | Allergan, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007134085-A2 | ISOTHIAZOLIDINES USEFUL IN THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | ALLERGAN, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007134085-A2 | ISOTHIAZOLIDINES USEFUL IN THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | ALLERGAN, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-4087435-A | 8-Aza-9-dioxothiaprostanoic acids | MERCK & CO., INC. (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247594-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | ALDH1A1 374/4885CA1 1304/4885CA2 877/4885 |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | ALDH1A1 374/4885CA1 1304/4885CA2 877/4885 |
| US-20090233931-A1 | THERAPEUTIC COMPOUNDS | SLC10A1, ABCB11, ACER2 | ALDH1A1 177/4885CA1 433/4885CA2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.